期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC 被引量:4
1
作者 Andreas Geier Carsten Gartung +3 位作者 christoph g.dietrich Hermann E.Wasmuth Patrick Reinartz Siegfried Matern 《World Journal of Gastroenterology》 SCIE CAS CSCD 2003年第12期2681-2685,共5页
AIM:To investigate the systemic availability of budesonide in a patient with Child A cirrhosis due to autoimmune hepatitis (AIH) and primary hepatocellular carcinoma,who developed serious side effects. METHODS:Serum l... AIM:To investigate the systemic availability of budesonide in a patient with Child A cirrhosis due to autoimmune hepatitis (AIH) and primary hepatocellular carcinoma,who developed serious side effects. METHODS:Serum levels of budesonide,6β-OH-budesonide and 16α-OH-prednisolon were measured by HPLC/MS/MS; portosystemic shunt-index (SI) was determined by 99mTc nuclear imaging.All values were compared with a matched control patient without side effects. RESULTS:Serum levels of budesonide were 13-fold increased in the index patient.The ratio between serum levels of the metabolites 6β-OH-budesonide and 16α-OH- prednisolone,respectively,and serum levels of budesonide was diminished (1.0 vs.4.0 for 6β-OH-budesonide,4.2 vs. 10.7 for 16α-OH-prednisolone).Both patients had portosystemic SI (5.7 % and 3.1%) within the range of healthy subjects.CONCLUSION:Serum levels of budesonide Vary uP to 13-fold in AIH Patients with Child A eirrhosis in the absenee ofrelevant Portosystemic shunting.Redueed hePatiemetabolism,as indicated by redueed metabolite-to-drugratio,rather than Portosystemie shunting may explainsystemic side effects of this drug in cirrhosis 展开更多
关键词 Portasystemic Shunt Surgical Aged Anti-Inflammatory Agents BUDESONIDE Carcinoma Hepatocellular Female Hepatitis Autoimmune Humans Liver Liver Neoplasms Research Support Non-U.S. Gov't
下载PDF
Occult celiac disease prevents penetrance of hemochromatosis
2
作者 Andreas Geier Carsten Gartung +7 位作者 Igor Theurl Guenter Weiss Frank Lammert christoph g.dietrich Ralf Weiskirchen Heinz Zoller Benita Hermanns Siegfried Matern 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第21期3323-3326,共4页
AIM:To report a patient with C282Y homozygocity,depleted body iron and intestinal atrophy caused by celiac disease (CD) who experienced resolution of the enteropathy with subsequent normalization of iron metabolism up... AIM:To report a patient with C282Y homozygocity,depleted body iron and intestinal atrophy caused by celiac disease (CD) who experienced resolution of the enteropathy with subsequent normalization of iron metabolism upon gluten free diet. METHODS:To obtain information on the tissue distribution and quantitative expression of proteins involved in duodenal iron trafficking,we determined the expression of divalent-metal transporter 1 (DMT1),ferroportin 1 (FP1) and transferrin receptor (TfR1) by means of immunohist-ochemistry and real-time PCR in duodenal biopsies of this patient. RESULTS:Whereas in hereditary hemochromatosis patients without CD, DMT1 expression was up-regulated leading to excessive uptake of iron, we identified a significant reduction in protein ana mRNA expression of DMT1 as a compensatory mechanism in this patient with HH and CD. CONCLUSION:Occult CD may compensate for increased DMT1 expression in a specific subset of individuals with homozygous C282Y mutations in the hemochromatosis (HFE) gene,thus contributing to the low penetrance of HH. 展开更多
关键词 HEMOCHROMATOSIS Celiac disease Divalentmetal transporter 1 Transferrin receptor Iron metabolism
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部